




RealRate

PHARMACEUTICAL 2026

Barinthus Biotherapeutics plc
Rank 60 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Barinthus Biotherapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Barinthus Biotherapeutics plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Barinthus Biotherapeutics plc is the variable Net Income, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 49% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	77,790
Cost of Goods Sold	0
Intangible Assets	14,288
Liabilities, Current	10,018
Liabilities, Non-Current	10,734
Other Assets	2,568
Other Compr. Net Income	10,167
Other Expenses	4,492
Other Liabilities	3,125
Other Net Income	3,922
Other Revenues	506
Property and Equipment	3,523
Research and Development	25,564
Selling, General and Administrative Expense	40,830

Output Variable	Value in 1000 USD
Assets	98,169
Liabilities	23,877
Expenses	70,886
Revenues	506
Stockholders Equity	74,292
Net Income	-66,458
Comprehensive Net Income	-61,374
BaseVar	103,764
ECR before LimitedLiability	165%
Economic Capital Ratio	278%